These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 19920896

  • 21. Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaire.
    Mukadi Y, Perriëns JH, St Louis ME, Brown C, Prignot J, Willame JC, Pouthier F, Kaboto M, Ryder RW, Portaels F.
    Lancet; 1993 Jul 17; 342(8864):143-6. PubMed ID: 8101257
    [Abstract] [Full Text] [Related]

  • 22. Increased soluble Fas in HIV-infected hemophilia patients with CD4+ and CD8+ cell count increases and viral load and immune complex decreases.
    Daniel V, Süsal C, Weimer R, Zimmermann R, Huth-Kühne A, Opelz G.
    AIDS Res Hum Retroviruses; 2001 Mar 01; 17(4):329-35. PubMed ID: 11242519
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy.
    Karo B, Krause G, Castell S, Kollan C, Hamouda O, Haas W, ClinSurv HIV Study Group.
    BMC Infect Dis; 2017 Jul 25; 17(1):517. PubMed ID: 28743248
    [Abstract] [Full Text] [Related]

  • 27. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.
    Habtewold A, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Burhenne J, Aklillu E.
    Pharmacogenomics; 2015 Jul 25; 16(10):1047-64. PubMed ID: 25831219
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.
    AIDS; 1999 Dec 03; 13(17):2377-88. PubMed ID: 10597779
    [Abstract] [Full Text] [Related]

  • 30. Changes in HIV RNA viral load, CD4+ T-cell counts, and levels of immune activation markers associated with anti-tuberculosis therapy and cotrimoxazole prophylaxis among HIV-infected tuberculosis patients in Abidjan, Cote d'Ivoire.
    Kalou M, Sassan-Morokro M, Abouya L, Bile C, Maurice C, Maran M, Tossou O, Roels T, Greenberg AE, Wiktor SZ, Nkengasong JN.
    J Med Virol; 2005 Feb 03; 75(2):202-8. PubMed ID: 15602734
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies.
    Fenner L, Atkinson A, Boulle A, Fox MP, Prozesky H, Zürcher K, Ballif M, Furrer H, Zwahlen M, Davies MA, Egger M, International Epidemiology Database to Evaluate AIDS in Southern Africa (IeDEA-SA).
    J Int AIDS Soc; 2017 Jun 23; 20(1):21327. PubMed ID: 28691438
    [Abstract] [Full Text] [Related]

  • 33. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Restoration of cellular immunity against tuberculosis in patients coinfected with HIV-1 and tuberculosis with effective antiretroviral therapy: assessment by determination of CD69 expression on T cells after tuberculin stimulation.
    Hsieh SM, Hung CC, Pan SC, Wang JT, Tsai HC, Chen MY, Chang SC.
    J Acquir Immune Defic Syndr; 2000 Nov 01; 25(3):212-20. PubMed ID: 11115951
    [Abstract] [Full Text] [Related]

  • 38. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
    Churchyard GJ, Snowden MA, Hokey D, Dheenadhayalan V, McClain JB, Douoguih M, Pau MG, Sadoff J, Landry B.
    Vaccine; 2015 Apr 08; 33(15):1890-6. PubMed ID: 25698492
    [Abstract] [Full Text] [Related]

  • 39. Characteristics of HIV-infected tuberculosis patients in Thailand.
    Mankatittham W, Likanonsakul S, Thawornwan U, Kongsanan P, Kittikraisak W, Burapat C, Akksilp S, Sattayawuthipong W, Srinak C, Nateniyom S, Tasaneeyapan T, Varma JK.
    Southeast Asian J Trop Med Public Health; 2009 Jan 08; 40(1):93-103. PubMed ID: 19323040
    [Abstract] [Full Text] [Related]

  • 40. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
    Vogler MA, Teppler H, Gelman R, Valentine F, Lederman MM, Pomerantz RJ, Pollard RB, Cherng DW, Gonzalez CJ, Squires KE, Frank I, Mildvan D, Mahon LF, Schock B, AIDS Clinical Trials Group 248 Study Team.
    J Acquir Immune Defic Syndr; 2004 May 01; 36(1):576-87. PubMed ID: 15097300
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.